Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 GBX | -20.00% | +4.92% | -45.76% |
May. 20 | London gets boost thanks to rate cut hopes | AN |
May. 20 | ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant | AN |
Sales 2023 | 9.6K 12.24K | Sales 2024 * | - | Capitalization | 4.24M 5.4M |
---|---|---|---|---|---|
Net income 2023 | -2M -2.55M | Net income 2024 * | - | EV / Sales 2023 | 791 x |
Net cash position 2023 * | 1.8M 2.29M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
P/E ratio 2023 |
-2.94
x | P/E ratio 2024 * |
-
| Employees | 8 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 83.27% |
1 day | -20.00% | ||
1 week | +4.92% | ||
Current month | -3.03% | ||
1 month | -7.25% | ||
3 months | -28.89% | ||
6 months | -68.78% | ||
Current year | -45.76% |
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Chief Tech/Sci/R&D Officer | - | 22-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
Director/Board Member | 57 | Feb. 28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 3.2 | -20.00% | 23,211,930 |
24-05-20 | 4 | +81.82% | 24,453,070 |
24-05-17 | 2.2 | +15.79% | 1,538,614 |
24-05-16 | 1.9 | 0.00% | 4,056,271 |
24-05-15 | 1.9 | -37.70% | 12,113,880 |
Delayed Quote London S.E., May 21, 2024 at 11:35 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.76% | 5.39M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- VAL Stock